Single-cell systems-level analysis of human Toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus - 06/11/15
Abstract |
Background |
Activation of Toll-like receptors (TLRs) induces inflammatory responses involved in immunity to pathogens and autoimmune pathogenesis, such as in patients with systemic lupus erythematosus (SLE). Although TLRs are differentially expressed across the immune system, a comprehensive analysis of how multiple immune cell subsets respond in a system-wide manner has not been described.
Objective |
We sought to characterize TLR activation across multiple immune cell subsets and subjects, with the goal of establishing a reference framework against which to compare pathologic processes.
Methods |
Peripheral whole-blood samples were stimulated with TLR ligands and analyzed by means of mass cytometry simultaneously for surface marker expression, activation states of intracellular signaling proteins, and cytokine production. We developed a novel data visualization tool to provide an integrated view of TLR signaling networks with single-cell resolution. We studied 17 healthy volunteer donors and 8 patients with newly diagnosed and untreated SLE.
Results |
Our data revealed the diversity of TLR-induced responses within cell types, with TLR ligand specificity. Subsets of natural killer cells and T cells selectively induced nuclear factor κ light chain enhancer of activated B cells in response to TLR2 ligands. CD14hi monocytes exhibited the most polyfunctional cytokine expression patterns, with more than 80 distinct cytokine combinations. Monocytic TLR-induced cytokine patterns were shared among a group of healthy donors, with minimal intraindividual and interindividual variability. Furthermore, autoimmune disease altered baseline cytokine production; newly diagnosed untreated SLE patients shared a distinct monocytic chemokine signature, despite clinical heterogeneity.
Conclusion |
Mass cytometry defined a systems-level reference framework for human TLR activation, which can be applied to study perturbations in patients with inflammatory diseases, such as SLE.
Le texte complet de cet article est disponible en PDF.Key words : Mass cytometry, Toll-like receptors, systemic lupus erythematosus, inflammation, monocytes, monocyte chemotactic protein 1
Abbreviations used : CD1c+ DC, CREB, MCP-1, MIP-1β, MyD88, NF-κB, NK, PAM, pDC, PRR, R848, SLE, TIR, TLR, TRIF
Plan
E.W.Y.H. is a Fellow of the Pediatric Scientist Development Program; supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development grant K12 HD000850, the Lucile Packard Foundation for Children's Health Stanford CTSA UL1 TR001085, and the Child Health Research Institute of Stanford University. E.S.S. is a National Science Foundation Graduate Research Fellow and Gabilon Stanford Graduate Research Fellow. P.F.G. is a Howard Hughes Medical Institute Fellow of the Life Sciences Research Foundation. J.D.H. is funded by the American Academy of Allergy Asthma and Immunology Mylan Anaphylaxis Research Award. L.H. is funded by the German Research Foundation DFG, HA 6772/1-1. I.M.B. is supported by National Institutes of Health (NIH) grant K08 AI080945, the Stanford Child Health Research Institute, and the Arthritis Foundation Postdoctoral Fellowship. D.B.L. is supported by funds from NIH grants R01 AI083757 and R01 AI100121. S.C.B. is supported by the Damon Runyon Cancer Research Foundation Fellowship (DRG-2017-09) and NIH R00 GM104148-03. This work is supported by funds from NIH grants U19AI057229, U19AI090019, U54CA149145, T32AI007290, N01-HV-00242, 1R01CA130826, R01GM109836, 1R01NS089533, P01 CA034233, 1U19AI100627, 5R01AI073724, R01CA184968, R33CA183654, and R33CA183692; HHSN272201200028C, 201303028, HHSN272200700038C, 5U54CA143907, 1149112 NIH–Baylor Research Institute 41000411217; NIH–Northrop Grumman Corp 7500108142; the California Institute for Regenerative Medicine DR1-01477; the US Food and Drug Administration HHSF223201210194C; the Bill and Melinda Gates Foundation OPP1113682; the European Commission HEALTH.2010.1.2-1; the Alliance for Lupus Research 218518; an Entertainment Industry Foundation NWCRA grant; US Department of Defense grants OC110674 and 11491122; Rachford and Carlota A. Harris Endowed Professorship; and the Howard Hughes Medical Institute. |
|
Disclosure of potential conflict of interest: W. E. O'Gorman has received research support from the National Institutes of Health (NIH; T32-AI007290) and has received personal fees as a paid speaker for DVS/Fluidigm Sciences. E. W. Y. Hsieh has received research support from the Pediatric Scientist Development Program (K12-HD000850) and the Lucile Packard Foundation for Children's Health (Stanford CTSA UL1 TR001085) and has received personal fees as a paid speaker for DVS/Fluidigm Sciences. E. S. Savig has received research support from the National Science Foundation Research Fellowship and the Gabilon Stanford Graduate Research Fellowship. P. F. Gherardini has received research support from the Life Sciences Research Foundation. J. D. Hernandez has received research support from the American Academy of Allergy, Asthma & Immunology. L. Hansmann has received research support from the German Research Foundation (DFG, HA 6772/1-1). I. M. Balboni has received research support from the NIH (K08-AI-080945), the Arthritis Foundation, and the Stanford Child Health Research Program Pilot Grant for Early Career Investigators. S. C. Bendall has received research support from the Damon Runyon Cancer Research Foundation (DRG-2017-09) and the NIH (R00 GM104148-03) and has received personal fees as a paid consultant for DVS Sciences. D. B. Lewis has received research support from the NIH (R01 AI083757 and R01 AI100121). G. P. Nolan has received research support from the NIH as follows: U19 AI057229, 1U19AI100627, U54 CA149145, N01-HV-00242, 1R01CA130826, 5R01AI073724, R01GM109836, R01CA184968, 1R01NS089533, P01 CA034233, R33 CA183654, R33 CA183692, 41000411217, 201303028, HHSN272201200028C, HHSN272200700038C, 5U54CA143907; CIRM DR1-01477; Department of Defense OC110674, 11491122; FDA HHSF223201210194C; Bill and Melinda Gates Foundation OPP1113682; Alliance for Lupus Research 218518; and a Rachford and Carlota A. Harris Endowed Professorship. Additionally, he has received support from DVS/Fluidigm Sciences and Becton Dickinson outside of the submitted work. M. M. Davis has received research support from the Howard Hughes Medical Institute and the NIH (U19-AI057229 and U19-AI090019). The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 136 - N° 5
P. 1326-1336 - novembre 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?